FDA Fast Track Designation Boosts ALS Treatment Outlook; Analyst Sees More Than 250% Upside Potential
Research Report
Biotech Co. Advances AI Detection Breakthrough for Intoxication Safety
California Biotech Co. Discovers VOXZOGO Breakthrough, Reports Strong Q1
Biotech Innovator Niagen Uncovers Breakthrough NAD+ Booster, Reports Strong Q1 Results
This article is issued on behalf of Aspire Biopharma Holdings, Inc. Sublingual Drug Reformulator Expands into Caffeine Market and Gets Capital Injection
Contributed Technical Analyst Opinion 
Technical Analyst Stewart Thomson reviews Aspire Biopharma Holdings, Inc. (ASBP:NASDAQ) in light of its recent news.
CleanTech Company Advances Global PFAS Water Treatment Partnership with Aquatech
FDA Rejects Melanoma Drug Again as Analysts Slash Targets and Approval Path Comes Under Fire
Oncology Company Given Neutral Rating as Q1/26 Beat Sets Up Catalyst
Research Report
Wedbush Securities reiterated a Neutral rating on Novocure Ltd. (NVCR:NASDAQ) after the company posted a Q1/26 revenue beat of US$174.1 million, raised FY26 guidance to US$690710 million, and reported encouraging early Optune Pax launch metrics. Three AI-Driven Cancer Programs Advance Toward Key 2026 Milestones
Rakovina Therapeutics Inc. (RKV:TSX.V) reported 2025 financial results and outlined progress across its kt-5000, kt-3283, and kt-2000 programs, alongside financing, leadership updates, and ongoing AI partnerships.Oncology Co. Tests Advanced Cancer Treatments, Reports Q1 2026 Financial Results
Novocure Ltd. (NVCR:NASDAQ) posted 12% revenue growth, strong international patient gains, FDA momentum, and promising pancreatic cancer trial results in 2026.MA Biotech Downgraded to Neutral After Second FDA CRL for RP1 Melanoma BLA
Research Report
Wedbush Securities downgraded Replimune Group Inc. (NASDAQ:REPL) to NEUTRAL after the FDA issued a second complete response letter for RP1 in PD-1 refractory melanoma. Biotech Downgraded to Neutral After Second FDA CRL for Reproxalap in Dry Eye Disease
Research Report
H.C. Wainwright & Co. downgraded Aldeyra Therapeutics Inc. (ALDX:NASDAQ) to Neutral and slashed its price target after the company received a second FDA Complete Response Letter for its Reproxalap NDA in dry eye disease. Biotech Co. Faces Mounting ELEVIDYS Efficacy Risk as Roche Phase 3 Study Threatens US Franchise
Research Report
H.C. Wainwright analysts argue that Roche's new placebo-controlled Phase 3 study of ELEVIDYS, while aimed at reopening the European market, creates significant downside risk for Sarepta Therapeutics Inc.'s (SRPT:NASDAQ) core U.S. ambulatory business by potentially generating another failed NSAA readout. Wedbush Sees Denifanstat as Front-Line Acne Therapy with 249% Upside Potential
Research Report
Wedbush Securities analyst Dr. Yun Zhong reiterated a price target on Sagimet Biosciences (SGMT:NASDAQ), implying roughly 249% upside. 
Streetwise Key Charts
